1 month ago
On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were "material, not theoretical." The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its best-selling HIV drug Biktarvy.
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.
#gild
2 months ago
Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $185.9 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
Companies with a market cap of $10 billion or more are typically referred to as "large-cap stocks." GILD fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the general drug manufacturers industry.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ******* eX Deal Could Meaningfully Accelerate Growth for Technip Stock
#gild #deal #Stock #sciences
Companies with a market cap of $10 billion or more are typically referred to as "large-cap stocks." GILD fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the general drug manufacturers industry.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ******* eX Deal Could Meaningfully Accelerate Growth for Technip Stock
#gild #deal #Stock #sciences
2 months ago
LONDON (AP) — Brazil forward Gabriel Martinelli ended a seven-year spell at ***** nal by joining Saudi Pro League team Al-Hilal on Thursday.
Arsenal announced the deal on X, saying: "Thank you for everything and best of luck, Gabi."
No fee was disclosed but media reports put it at 60 million pounds ($81.2 million), which would make the 25-year-old Martinelli the English Premier League champion's most lucrative transfer departure.
It eclipses former midfielder Alex Oxlade Chamberlain's 35 million pounds ($46.3 million) exit to Liverpool in 2017.
Martinelli's move to the Saudi Pro League comes after fellow left-sided forward Leandro Trossard was sold to Besiktas last month.
#martinelli #arsenal #pounds #Brazil
Arsenal announced the deal on X, saying: "Thank you for everything and best of luck, Gabi."
No fee was disclosed but media reports put it at 60 million pounds ($81.2 million), which would make the 25-year-old Martinelli the English Premier League champion's most lucrative transfer departure.
It eclipses former midfielder Alex Oxlade Chamberlain's 35 million pounds ($46.3 million) exit to Liverpool in 2017.
Martinelli's move to the Saudi Pro League comes after fellow left-sided forward Leandro Trossard was sold to Besiktas last month.
#martinelli #arsenal #pounds #Brazil
2 months ago
With the summer transfer window slamming shut soon, the future of Marc Casado will likely dominate the headlines for now.
The midfielder has yet to secure an exit from Camp Nou despite having been identified as surplus to requirements by Hansi Flick and his troops.
RB Leipzig were credited with interest in the midfielder recently but have since dropped the pursuit. That leaves Besiktas as the ones firmly in focus.
Casado has no place in the Barcelona team. (Photo by Alex Livesey/Getty Images)
According to Diario SPORT, Besiktas have been one of the most interested clubs since the start of the summer and have intensified their pressure in recent days to convince both Barcelona and the player to sanction a move.
#since #camp
The midfielder has yet to secure an exit from Camp Nou despite having been identified as surplus to requirements by Hansi Flick and his troops.
RB Leipzig were credited with interest in the midfielder recently but have since dropped the pursuit. That leaves Besiktas as the ones firmly in focus.
Casado has no place in the Barcelona team. (Photo by Alex Livesey/Getty Images)
According to Diario SPORT, Besiktas have been one of the most interested clubs since the start of the summer and have intensified their pressure in recent days to convince both Barcelona and the player to sanction a move.
#since #camp
2 months ago
On Friday, TSG Hoffenheim and Bayer Leverkusen found out which teams they will face in the league phase of the Europa League this season. Last season's fifth-placed team Hoffenheim were in Pot 4, while the 2023/24 finalists were drawn out of Pot 1.
Carles Martínez's side will face Ligue 1 sides Marseille and Lyon from the top ranks, while home games against RB Salzburg and Beşiktaş are also standout fixtures. Hoffenheim will also face Lyon and Beşiktaş, in addition to tricky trips to Olympiacos, Anderlecht and Conference League champions Crystal Palace.
Here is a breakdown of who Hoffenheim and Leverkusen will face during the league phase starting 10 September 2026 and ending 28 January 2027.
Marseille (H)
Lyon (A)
#league #leverkusen #Friday
Carles Martínez's side will face Ligue 1 sides Marseille and Lyon from the top ranks, while home games against RB Salzburg and Beşiktaş are also standout fixtures. Hoffenheim will also face Lyon and Beşiktaş, in addition to tricky trips to Olympiacos, Anderlecht and Conference League champions Crystal Palace.
Here is a breakdown of who Hoffenheim and Leverkusen will face during the league phase starting 10 September 2026 and ending 28 January 2027.
Marseille (H)
Lyon (A)
#league #leverkusen #Friday
2 months ago
The Europa League draw has also been completed and has given us some highlights for this season. You can find out which matches you can look forward to in our overview.
Bayer Leverkusen: Olympique Marseille (H), Olympique Lyon (A), RB Salzburg (H), Dinamo Zagreb (A), NK Celje (H), Lech Poznan (A), Besiktas (H), OF Iraklion (A).
Benfica Lisbon: AZ Alkmaar (H), AC Milan (A), Celtic Glasgow (H), Viktoria Plzen (A), Lech Poznan (H), Omonia Nicosia (A), OF Iraklion (H), NEC Nijmegen (A).
Juventus Turin: Real Sociedad (H), Alkmaar (A), Stade Rennes (H), Ferencvaros (A), Omonia (H), Celta Vigo (A), NEC Nijmegen (H), Hapoel Beer Sheva (A).
Olympique Lyon: Bayer Leverkusen (H), Real Sociedad (A), Union Saint-Gilloise (H), Anderlecht (A), Crystal Palace (H), Jagiellonia (A), Lillestrøm (H), TSG Hoffenheim (A).
#olympique #lech
Bayer Leverkusen: Olympique Marseille (H), Olympique Lyon (A), RB Salzburg (H), Dinamo Zagreb (A), NK Celje (H), Lech Poznan (A), Besiktas (H), OF Iraklion (A).
Benfica Lisbon: AZ Alkmaar (H), AC Milan (A), Celtic Glasgow (H), Viktoria Plzen (A), Lech Poznan (H), Omonia Nicosia (A), OF Iraklion (H), NEC Nijmegen (A).
Juventus Turin: Real Sociedad (H), Alkmaar (A), Stade Rennes (H), Ferencvaros (A), Omonia (H), Celta Vigo (A), NEC Nijmegen (H), Hapoel Beer Sheva (A).
Olympique Lyon: Bayer Leverkusen (H), Real Sociedad (A), Union Saint-Gilloise (H), Anderlecht (A), Crystal Palace (H), Jagiellonia (A), Lillestrøm (H), TSG Hoffenheim (A).
#olympique #lech
2 months ago
Olympique de Marseille, Olympique Lyonnais and Stade Rennais now know what lies ahead.
The draw for the Europa League league phase delivered its verdict on Friday afternoon in Monaco. The three French clubs involved in the competition now know their eight opponents.
OM and OL will both go head-to-head with one of the overwhelming favorites for this edition: Bayer Leverkusen. A daunting common denominator!
Marseille will also have to navigate tricky away trips to Celtic Glasgow and Beşiktaş.
Rennes will take on the other giant of the competition: Juventus.
#head
The draw for the Europa League league phase delivered its verdict on Friday afternoon in Monaco. The three French clubs involved in the competition now know their eight opponents.
OM and OL will both go head-to-head with one of the overwhelming favorites for this edition: Bayer Leverkusen. A daunting common denominator!
Marseille will also have to navigate tricky away trips to Celtic Glasgow and Beşiktaş.
Rennes will take on the other giant of the competition: Juventus.
#head
2 months ago
After the Bundesliga clubs already found out yesterday who they will face in the Champions League, Bayer Leverkusen now also knows its opponents for the coming Europa League season.
The draw has just produced the following opponents.
Olympique Marseille (H), Olympique Lyon (A), RB Salzburg (H), Dinamo Zagreb (A), NK Celje (H), Lech Poznań (A), Beşiktaş (H), OF Iraklion (A).
The league phase begins on September 16, with UEFA set to announce the exact schedule and dates in the coming days. Next year's final, meanwhile, will be held in Frankfurt.
Are these manageable opponents for Leverkusen? What do you think? Feel free to share your opinion in the comments.
#champions
The draw has just produced the following opponents.
Olympique Marseille (H), Olympique Lyon (A), RB Salzburg (H), Dinamo Zagreb (A), NK Celje (H), Lech Poznań (A), Beşiktaş (H), OF Iraklion (A).
The league phase begins on September 16, with UEFA set to announce the exact schedule and dates in the coming days. Next year's final, meanwhile, will be held in Frankfurt.
Are these manageable opponents for Leverkusen? What do you think? Feel free to share your opinion in the comments.
#champions
2 months ago
Juventus are continuing to trim fat, but it's still not enough to finally table their offer for Frank Kessié, and Roma have entered the race, joining Al-Ittihad and other Saudi sides that would cover him in gold to keep him in their league, La Gazzetta dello Sport informs.
After releasing Arthur Melo, the Bianconeri will bid farewell to Fabio Miretti. He'll move to Besiktas, like Dusan Vlahovic, on a loan with a conditional obligation to buy. The Old Lady also completed Michele Di Gregorio's exit and Kamil Grabara's arrival, with a temporary formula with a €12M acquisition clause. Instead, Mattia Perin transferred to Palermo on a €500k move.
On the other hand, the recent departures don't suffice yet for Juventus to really step up their Kessié pursuit. They have to find a solution for the burdensome Teun Koopmeiners, Jonathan David, and Nicolas Gonzalez. Juan Cabal and Arkadiusz Milik are also on the chopping block.
In the meantime, Roma have shown some interest in the Ivorian powerhouse, who broke out under Gian Piero Gasperini at Atalanta. They have skirted the Manchester United threat for Manu Koné, as the Red Devils completed their midfield with Carlos Baleba. Other sides could be keen on him, but Neil El Aynaoui is a more precarious spot now.
They shouldn't waste any more time and should sign him in after managing to have a hold on him for so long, and worry about the departures later. Koopmeiners is the main Gordian knot, but there may also be issues with his personal terms. It's been a while since the capital club signed a veteran with bloated wages, even though Gasperini surely wouldn't mind.
#frank
After releasing Arthur Melo, the Bianconeri will bid farewell to Fabio Miretti. He'll move to Besiktas, like Dusan Vlahovic, on a loan with a conditional obligation to buy. The Old Lady also completed Michele Di Gregorio's exit and Kamil Grabara's arrival, with a temporary formula with a €12M acquisition clause. Instead, Mattia Perin transferred to Palermo on a €500k move.
On the other hand, the recent departures don't suffice yet for Juventus to really step up their Kessié pursuit. They have to find a solution for the burdensome Teun Koopmeiners, Jonathan David, and Nicolas Gonzalez. Juan Cabal and Arkadiusz Milik are also on the chopping block.
In the meantime, Roma have shown some interest in the Ivorian powerhouse, who broke out under Gian Piero Gasperini at Atalanta. They have skirted the Manchester United threat for Manu Koné, as the Red Devils completed their midfield with Carlos Baleba. Other sides could be keen on him, but Neil El Aynaoui is a more precarious spot now.
They shouldn't waste any more time and should sign him in after managing to have a hold on him for so long, and worry about the departures later. Koopmeiners is the main Gordian knot, but there may also be issues with his personal terms. It's been a while since the capital club signed a veteran with bloated wages, even though Gasperini surely wouldn't mind.
#frank
2 months ago
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#gild #increased
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#gild #increased
2 months ago
The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in one therapeutic area. For investors, this is ultimately a choice between an unfinished turnaround and a stronger growth story still searching for greater breadth.
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
2 months ago
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#product
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.
#product
2 months ago
Multiple outlets in Italy are reporting that Juventus and Turkish Super Lig club Besiktas are in direct negotiations over a potential deal for midfielder Fabio Miretti and that the two sides are currently discussing the 'formula' of the transfer.
Juventus have already added Randal Kolo Muani, Kerim Alajbegovic, Guglielmo Vicario, Jhon Lucumi, Jeff Ekhator and Zeki Celik to their ranks this summer but are still hoping to add a few more signings to the list before the close of the transfer window.
"In general we've had a good transfer market, some areas need a few cosmetic changes, others entire restoration projects," said head coach Luciano Spalletti during a press conference on Saturday.
In order for those new signings to come in, other players must first be sold, and according to the latest updates, Miretti could be one of those players that ends up on the chopping block.
According to reports from various sources on Sunday including Sky Sport Italia's Gianluca Di Marzio, Juventus are in direct discussions with Besiktas to discuss the sale of Miretti.
#juventus #according #italy
Juventus have already added Randal Kolo Muani, Kerim Alajbegovic, Guglielmo Vicario, Jhon Lucumi, Jeff Ekhator and Zeki Celik to their ranks this summer but are still hoping to add a few more signings to the list before the close of the transfer window.
"In general we've had a good transfer market, some areas need a few cosmetic changes, others entire restoration projects," said head coach Luciano Spalletti during a press conference on Saturday.
In order for those new signings to come in, other players must first be sold, and according to the latest updates, Miretti could be one of those players that ends up on the chopping block.
According to reports from various sources on Sunday including Sky Sport Italia's Gianluca Di Marzio, Juventus are in direct discussions with Besiktas to discuss the sale of Miretti.
#juventus #according #italy
2 months ago
Celtic continue their pursuit of midfield options as Rangers prepare for a big name departure...
Celtic will step up their interest in Torino midfielder Gvidas Gineitis, 22, after Tuesday's Champions League play-off second leg away to LASK. (Scottish Sun)
Celtic are set to seal a £7m move for 21-year-old Bosnian World Cup star Ermin Mahmic from Slovan Liberec regardless of their Champions League result in Linz. (Daily Record)
Celtic have offered £7.7m for Frosinone winger Fares Ghedjemis, who is also being courted by Rangers, Monaco and Besiktas. (Murat Ozen on X)
Rangers have received initial approaches from England, Italy and Spain regarding Nico Raskin and will allow the Belgium midfielder, who has two years left on his contract, to depart if their valuation is met. (Rangers Review)
#celtic #rangers #midfielder
Celtic will step up their interest in Torino midfielder Gvidas Gineitis, 22, after Tuesday's Champions League play-off second leg away to LASK. (Scottish Sun)
Celtic are set to seal a £7m move for 21-year-old Bosnian World Cup star Ermin Mahmic from Slovan Liberec regardless of their Champions League result in Linz. (Daily Record)
Celtic have offered £7.7m for Frosinone winger Fares Ghedjemis, who is also being courted by Rangers, Monaco and Besiktas. (Murat Ozen on X)
Rangers have received initial approaches from England, Italy and Spain regarding Nico Raskin and will allow the Belgium midfielder, who has two years left on his contract, to depart if their valuation is met. (Rangers Review)
#celtic #rangers #midfielder
2 months ago
1st March 2026; Ibrox; Scottish Premiership , Rangers versus Celtic; Alex Oxlade Chamberlain of Celtic. Photo Vagelis Georgariou Celtic Shorts
The midfielder extended his stay at the Hoops over the summer after making an important contribution under Martin O'Neill last season, but will now have to wait for his European debut in a Celtic shirt.
Credit to John McGinley from TCW for his reporting on this, Oxlade-Chamberlain is still serving a three-match UEFA suspension dating back to his final European appearance for Besiktas.
The former Liverpool and **** nal midfielder was shown a straight red card against Lugano in the UEFA Conference League after lashing out at opposition winger Renato Steffen, who was also dismissed.
The incident resulted in a three-match ban which carries over to his time at Celtic.
#celtic #oxlade #chamberlain
The midfielder extended his stay at the Hoops over the summer after making an important contribution under Martin O'Neill last season, but will now have to wait for his European debut in a Celtic shirt.
Credit to John McGinley from TCW for his reporting on this, Oxlade-Chamberlain is still serving a three-match UEFA suspension dating back to his final European appearance for Besiktas.
The former Liverpool and **** nal midfielder was shown a straight red card against Lugano in the UEFA Conference League after lashing out at opposition winger Renato Steffen, who was also dismissed.
The incident resulted in a three-match ban which carries over to his time at Celtic.
#celtic #oxlade #chamberlain
2 months ago
Photo by Stefano Guidi/Getty Images
Dušan Vlahović has finally brought the curtain down on his time at Juventus, with the former ***** nal target completing a free transfer to Beşiktaş after years of speculation linking him with a move to north London.
The Serbia international has signed a three-year contract until June 2029 after leaving Juventus at the end of his deal, ending a four-and-a-half-year spell in Turin during which he scored 68 goals, with 16 ***** ists, in 168 games.
Vlahović's move unites him with former ***** nal forward Leandro Trossard, who also joined Beşiktaş this summer, while bringing an end to one of the transfer sagas that repeatedly resurfaced around the Emirates.
Photo by Ahmad Mora/Getty Images
#vlahovi #juventus #move
Dušan Vlahović has finally brought the curtain down on his time at Juventus, with the former ***** nal target completing a free transfer to Beşiktaş after years of speculation linking him with a move to north London.
The Serbia international has signed a three-year contract until June 2029 after leaving Juventus at the end of his deal, ending a four-and-a-half-year spell in Turin during which he scored 68 goals, with 16 ***** ists, in 168 games.
Vlahović's move unites him with former ***** nal forward Leandro Trossard, who also joined Beşiktaş this summer, while bringing an end to one of the transfer sagas that repeatedly resurfaced around the Emirates.
Photo by Ahmad Mora/Getty Images
#vlahovi #juventus #move
2 months ago
Photo by Ahmad Mora/Getty Images
Leandro Trossard has made his first appearance for Beşiktaş, helping the Turkish club move a step closer to the Europa League group stage this week.
The former ***** nal forward came off the bench as Beşiktaş completed the job against Hradec Králové, offering supporters their first glimpse of a player who left north London after three and a half successful years.
Introduced in the 66th minute of Thursday's Europa League third qualifying round second leg, Trossard helped see out a 1-0 victory that secured a 2-0 aggregate win and booked Beşiktaş's place in the play-off round.
The evening's only goal came from Vaclav Cerny in the 40th minute, before Trossard was handed his first minutes.
#trossard
Leandro Trossard has made his first appearance for Beşiktaş, helping the Turkish club move a step closer to the Europa League group stage this week.
The former ***** nal forward came off the bench as Beşiktaş completed the job against Hradec Králové, offering supporters their first glimpse of a player who left north London after three and a half successful years.
Introduced in the 66th minute of Thursday's Europa League third qualifying round second leg, Trossard helped see out a 1-0 victory that secured a 2-0 aggregate win and booked Beşiktaş's place in the play-off round.
The evening's only goal came from Vaclav Cerny in the 40th minute, before Trossard was handed his first minutes.
#trossard
2 months ago
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.
Merck & Co., Inc. delivered $16.3 billion in total sales for the first quarter of 2026, up 5% year-over-year (3% excluding foreign exchange). Top-line growth continued to be anchored by its flagship oncology therapy, Keytruda, which, alongside its sub-formulations, brought in $8.0 billion in sales, representing an 8% ex-exchange increase. Pulmonary arterial hypertension treatment Winrevair also contributed strongly with $525 million in quarterly revenue, up 87% ex-exchange. GAAP and non-GAAP bottom-line metrics reflected net losses per share of $1.72 and $1.28, respectively, largely driven by upfront charges tied to the strategic acquisition of Cidara Therapeutics. Despite those acquisition-related charges, Merck narrowed and raised the midpoint of its full-year worldwide sales guidance to between $65.8 billion and $67.0 billion.
Merck's growth story remains heavily reliant on expanding Keytruda's reach into earlier-stage treatments and novel combination regimens. With key patent expirations approaching toward the end of the decade, management has aggressively pursued business development and combination therapies to diversify its revenue base and maintain its dominance in immuno-oncology.
Gilead Sciences, Inc. reported $7.0 billion in total revenue for the first quarter of 2026, posting 5% year-over-year product sales growth. Gilead's base business, excluding COVID-19 treatment Veklury, rose 8% year-over-year to $6.8 billion, powered by its market-leading HIV franchise, which generated $5.0 billion in sales (up 10% year-over-year). Biktarvy remained the primary growth driver, while newly launched therapies like Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis provided fresh momentum. The corporation's adjusted diluted earnings per share reached $2.03.
Backed by strong demand across its core virology portfolio, Gilead Sciences, Inc. raised its full-year 2026 total product sales guidance range by $400 million, targeting $30.0 billion to $30.4 billion.
#billion #merck #sciences #oncology
Merck & Co., Inc. delivered $16.3 billion in total sales for the first quarter of 2026, up 5% year-over-year (3% excluding foreign exchange). Top-line growth continued to be anchored by its flagship oncology therapy, Keytruda, which, alongside its sub-formulations, brought in $8.0 billion in sales, representing an 8% ex-exchange increase. Pulmonary arterial hypertension treatment Winrevair also contributed strongly with $525 million in quarterly revenue, up 87% ex-exchange. GAAP and non-GAAP bottom-line metrics reflected net losses per share of $1.72 and $1.28, respectively, largely driven by upfront charges tied to the strategic acquisition of Cidara Therapeutics. Despite those acquisition-related charges, Merck narrowed and raised the midpoint of its full-year worldwide sales guidance to between $65.8 billion and $67.0 billion.
Merck's growth story remains heavily reliant on expanding Keytruda's reach into earlier-stage treatments and novel combination regimens. With key patent expirations approaching toward the end of the decade, management has aggressively pursued business development and combination therapies to diversify its revenue base and maintain its dominance in immuno-oncology.
Gilead Sciences, Inc. reported $7.0 billion in total revenue for the first quarter of 2026, posting 5% year-over-year product sales growth. Gilead's base business, excluding COVID-19 treatment Veklury, rose 8% year-over-year to $6.8 billion, powered by its market-leading HIV franchise, which generated $5.0 billion in sales (up 10% year-over-year). Biktarvy remained the primary growth driver, while newly launched therapies like Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis provided fresh momentum. The corporation's adjusted diluted earnings per share reached $2.03.
Backed by strong demand across its core virology portfolio, Gilead Sciences, Inc. raised its full-year 2026 total product sales guidance range by $400 million, targeting $30.0 billion to $30.4 billion.
#billion #merck #sciences #oncology
3 months ago
As expected, former Juventus and Fiorentina striker Dusan Vlahovic is travelling to Istanbul to sign for Besiktas as a free agent, reuniting with coach Vincenzo Italiano.
The centre-forward was out of contract since his agreement with Juve was allowed to expire on June 30.
He had been hoping for another Serie A switch to Napoli or Milan, with an eye on potential Premier League interest from ******* nal and Chelsea, plus Barcelona or Atletico Madrid in LaLiga.
However, none of them were willing to meet his wage demands, so he relented and accepted the offer from Besiktas.
LECCE, ITALY – MAY 09: Dusan Vlahovic of Juventus FC celebrates the opening goal during the Serie A match between US Lecce and Juventus FC at Stadio Via del Mare on May 09, 2026 in Lecce, Italy. (Photo by Maurizio Lagana/Getty Images)
#vlahovic #serie #vincenzo
The centre-forward was out of contract since his agreement with Juve was allowed to expire on June 30.
He had been hoping for another Serie A switch to Napoli or Milan, with an eye on potential Premier League interest from ******* nal and Chelsea, plus Barcelona or Atletico Madrid in LaLiga.
However, none of them were willing to meet his wage demands, so he relented and accepted the offer from Besiktas.
LECCE, ITALY – MAY 09: Dusan Vlahovic of Juventus FC celebrates the opening goal during the Serie A match between US Lecce and Juventus FC at Stadio Via del Mare on May 09, 2026 in Lecce, Italy. (Photo by Maurizio Lagana/Getty Images)
#vlahovic #serie #vincenzo
3 months ago
For months, Dušan Vlahović's career has been all but speculation.
After a will-they-won't-they phase with Juventus, it was finally confirmed that the Serbian would leave Turin, only to be plunged into the next phase of uncertainty.
Now, that is drawing to a close. As confirmed by TUTTOmercatoWEB, the 26-year-old has agreed a three-year deal with Beşiktaş.
In İstanbul, he is set to team up with Vincenzo Italiano again, with whom he achieved breakthrough success at Fiorentina that prompted Juve to splurge €75 million to bring him to Allianz Arena.
As reported by Corriere dello Sport, Vlahović is set to earn a net annual salary of €8 million per year at Beşiktaş plus add-ons, including a sign-on bonus ranging between €15 and €20 million.
#vlahovi #confirmed #ikta #juventus
After a will-they-won't-they phase with Juventus, it was finally confirmed that the Serbian would leave Turin, only to be plunged into the next phase of uncertainty.
Now, that is drawing to a close. As confirmed by TUTTOmercatoWEB, the 26-year-old has agreed a three-year deal with Beşiktaş.
In İstanbul, he is set to team up with Vincenzo Italiano again, with whom he achieved breakthrough success at Fiorentina that prompted Juve to splurge €75 million to bring him to Allianz Arena.
As reported by Corriere dello Sport, Vlahović is set to earn a net annual salary of €8 million per year at Beşiktaş plus add-ons, including a sign-on bonus ranging between €15 and €20 million.
#vlahovi #confirmed #ikta #juventus
3 months ago
Serbian striker Dušan Vlahović is still without a club despite reports saying he wanted to make a decision by the end of last week. Barcelona remain his dream destination according to rumor, but the only club to have made a solid proposal that matches his demands is Beşiktaş.
Vlahović left Juventus after the Italians refused to acquiesce to his salary and signing bonus demands. He's tested the open market and found top European clubs such as Barça and Atlético Madrid were willing to speak to him, but less willing to actually sign him.
Reports say that Vlahović is willing to drop his financial demands to sign for a top club, especially Barcelona. But considering how high his original demands were, that may not be enough. Beşiktaş want him to accept their deal, which is quite hefty, and forget about Barça. But the player himself has obviously not done so, and is seemingly still holding out hope that the Catalans bite.
One development that could play strongly in his favor is the looming sale of Ferran Torres to PSG. If the World Cup hero is sold, Barcelona will be without their top two strikers from last season, with Robert Lewandowski having already left for Chicago Fire. Signing a striker will go from a top priority, to a necessity. In fact, Barça may have to sign two strikers in that case.
With other options such as Julián Alvarez looking increasingly likely, there is a line of thought that says Vlahović to Barcelona is the compromise that's just a matter of time. But the biggest hurdle to overcome is a lack of enthusiasm for the signing from the Catalans' part. If they were truly keen, they could have snapped him up any time.
#vlahovi
Vlahović left Juventus after the Italians refused to acquiesce to his salary and signing bonus demands. He's tested the open market and found top European clubs such as Barça and Atlético Madrid were willing to speak to him, but less willing to actually sign him.
Reports say that Vlahović is willing to drop his financial demands to sign for a top club, especially Barcelona. But considering how high his original demands were, that may not be enough. Beşiktaş want him to accept their deal, which is quite hefty, and forget about Barça. But the player himself has obviously not done so, and is seemingly still holding out hope that the Catalans bite.
One development that could play strongly in his favor is the looming sale of Ferran Torres to PSG. If the World Cup hero is sold, Barcelona will be without their top two strikers from last season, with Robert Lewandowski having already left for Chicago Fire. Signing a striker will go from a top priority, to a necessity. In fact, Barça may have to sign two strikers in that case.
With other options such as Julián Alvarez looking increasingly likely, there is a line of thought that says Vlahović to Barcelona is the compromise that's just a matter of time. But the biggest hurdle to overcome is a lack of enthusiasm for the signing from the Catalans' part. If they were truly keen, they could have snapped him up any time.
#vlahovi
3 months ago
A year ago, they were three of the main faces of Serie A. Today, Romelu Lukaku, Dusan Vlahovic and Rafael Leao are facing a scenario that would have been unthinkable just a few months ago: move to Turkey to remain key players, or accept a backup role in Europe's biggest leagues.
Follow Napoli's pre-season training camp up close! The friendly against Aris Thessaloniki will be broadcast live on OneFootball! Click here to check the match schedule and how to watch.
Fenerbahçe, Beşiktaş and Galatasaray are ready to welcome them as superstars.
The big clubs in the Premier League, La Liga and the Bundesliga, on the other hand, seem willing to take them only under very different conditions: lower wages, more competition and no guarantees of a starting spot.
An unthinkable scenario for three players of their caliber, all of them standout stars in the Italian league.
#players #romelu #lukaku
Follow Napoli's pre-season training camp up close! The friendly against Aris Thessaloniki will be broadcast live on OneFootball! Click here to check the match schedule and how to watch.
Fenerbahçe, Beşiktaş and Galatasaray are ready to welcome them as superstars.
The big clubs in the Premier League, La Liga and the Bundesliga, on the other hand, seem willing to take them only under very different conditions: lower wages, more competition and no guarantees of a starting spot.
An unthinkable scenario for three players of their caliber, all of them standout stars in the Italian league.
#players #romelu #lukaku
3 months ago
Milan legend Roberto Donadoni reveals how he would've dealt with Rafael Leao in the dressing room. 'I'd grab him by the dreadlocks every now and then.'
The winger is looking to leave the club this summer, insisting that he is ready to move beyond the Rossoneri, but in turn the fans are frustrated with his inconsistent performances.
COMO, ITALY – JANUARY 15: Mike Maignan of AC Milan interacts with Rafael Leao during the Serie A match between Como 1907 and AC Milan at Giuseppe Sinigaglia Stadium on January 15, 2026 in Como, Italy. (Photo by Marco Luzzani/Getty Images)
That is also why the expected big offers have not flooded in this summer, as only Turkish teams like Galatasaray, Fenerbahce and Besiktas have made genuine approaches, and none are prepared to pay the €50m plus add-ons asking price.
MilanNews turned to club legend Donadoni to ask how he would've dealt with a teammate like Rafael Leao, and the response was not positive.
#leao #como #january
The winger is looking to leave the club this summer, insisting that he is ready to move beyond the Rossoneri, but in turn the fans are frustrated with his inconsistent performances.
COMO, ITALY – JANUARY 15: Mike Maignan of AC Milan interacts with Rafael Leao during the Serie A match between Como 1907 and AC Milan at Giuseppe Sinigaglia Stadium on January 15, 2026 in Como, Italy. (Photo by Marco Luzzani/Getty Images)
That is also why the expected big offers have not flooded in this summer, as only Turkish teams like Galatasaray, Fenerbahce and Besiktas have made genuine approaches, and none are prepared to pay the €50m plus add-ons asking price.
MilanNews turned to club legend Donadoni to ask how he would've dealt with a teammate like Rafael Leao, and the response was not positive.
#leao #como #january
3 months ago
Atletico Madrid have opened talks over a move for former Juventus striker Dusan Vlahovic, according to Sport.
Los Colchoneros are exploring the possibility of bringing the Serbia international to Spain on a free transfer.
Vlahovic became one of the most sought-after free agents in Europe after leaving Juventus following the expiration of his contract in Turin in June.
The 26-year-old has attracted interest from several clubs, including Manchester United, Barcelona and Besiktas.
However, Atletico's approach could prove particularly appealing after Vlahovic reportedly made the Spanish side his preferred destination.
#dusan #sport #colchoneros
Los Colchoneros are exploring the possibility of bringing the Serbia international to Spain on a free transfer.
Vlahovic became one of the most sought-after free agents in Europe after leaving Juventus following the expiration of his contract in Turin in June.
The 26-year-old has attracted interest from several clubs, including Manchester United, Barcelona and Besiktas.
However, Atletico's approach could prove particularly appealing after Vlahovic reportedly made the Spanish side his preferred destination.
#dusan #sport #colchoneros
3 months ago
Real Madrid have a very talented squad at Jose Mourinho's disposal, with many players competing for each position.
For a player like Brahim Diaz, the Moroccan attacking midfielder could have an important squad role to play even if he does not always feature as a starter.
The 27-year-old versatile star has been at the Spanish club for a few seasons now, playing important role off the bench.
Earlier this summer, it emerged that even if he cannot have a starring role, Brahim was still keen on staying at Real Madrid.
However, in recent days, talk of a potential move to Besiktas has emerged for the talented Real Madrid ace.
#brahim #important
For a player like Brahim Diaz, the Moroccan attacking midfielder could have an important squad role to play even if he does not always feature as a starter.
The 27-year-old versatile star has been at the Spanish club for a few seasons now, playing important role off the bench.
Earlier this summer, it emerged that even if he cannot have a starring role, Brahim was still keen on staying at Real Madrid.
However, in recent days, talk of a potential move to Besiktas has emerged for the talented Real Madrid ace.
#brahim #important
3 months ago
Mohamed Salah has arrived in Istanbul wearing a Trabzonspor shirt to finalise a move to the Turkish Super Lig side.
Hundreds of fans were on hand to greet the former Liverpool forward at Ataturk Airport after the club announced on Tuesday evening that he would travel to Trabzon via Istanbul.
In a video posted on the club's social media accounts, Salah said: "Trabzon, are you ready? I can hear you. See you very soon."
The 34-year-old is a free agent after leaving Liverpool this summer following nine years at the club, where he scored 257 times in 442 appearances and won two Premier League ***** les and the Champions League.
Salah has been linked with several clubs this summer, and had received an offer from Trabzonspor's Super Lig rivals Besiktas.
#istanbul #super
Hundreds of fans were on hand to greet the former Liverpool forward at Ataturk Airport after the club announced on Tuesday evening that he would travel to Trabzon via Istanbul.
In a video posted on the club's social media accounts, Salah said: "Trabzon, are you ready? I can hear you. See you very soon."
The 34-year-old is a free agent after leaving Liverpool this summer following nine years at the club, where he scored 257 times in 442 appearances and won two Premier League ***** les and the Champions League.
Salah has been linked with several clubs this summer, and had received an offer from Trabzonspor's Super Lig rivals Besiktas.
#istanbul #super
3 months ago
Besiktas President Serdal Adali confirmed they are 'talking to Dusan Vlahovic' about a deal for the former Juventus striker, after refusing to meet Mohamed Salah's terms.
The Turkish club is confident it has a secret weapon in tempting Vlahovic to the Super Lig, specifically the presence of coach Vincenzo Italiano, who already worked with the Serbian at Fiorentina.
The forward has been a free agent since July 1, when his contract with Juventus was allowed to run down.
TURIN, ITALY – MAY 03: Dusan Vlahovic of Juventus FC celebrates scoring his team's first goal during the Serie A match between Juventus FC and **** as Verona FC at Allianz Stadium on May 3, 2026 in Turin, Italy. (Photo by Valerio Pennicino/Getty Images)
He had left the door open for a potential new deal with Juve at a reduced salary, but has largely been waiting for the big clubs in the Premier League, LaLiga or Bundesliga to make him an offer.
#dusan #italy #besiktas #serdal
The Turkish club is confident it has a secret weapon in tempting Vlahovic to the Super Lig, specifically the presence of coach Vincenzo Italiano, who already worked with the Serbian at Fiorentina.
The forward has been a free agent since July 1, when his contract with Juventus was allowed to run down.
TURIN, ITALY – MAY 03: Dusan Vlahovic of Juventus FC celebrates scoring his team's first goal during the Serie A match between Juventus FC and **** as Verona FC at Allianz Stadium on May 3, 2026 in Turin, Italy. (Photo by Valerio Pennicino/Getty Images)
He had left the door open for a potential new deal with Juve at a reduced salary, but has largely been waiting for the big clubs in the Premier League, LaLiga or Bundesliga to make him an offer.
#dusan #italy #besiktas #serdal
3 months ago
Mohamed Salah's transfer saga has come to an end.
After leaving Anfield on a free transfer, he is joining Turkish Cup winners Trabzonspor. This is reported by transfer insider 'Fabrizio Romano' and Turkish transfer insider 'Yağız Sabuncuoğlu'.
Back in March, the Egyptian announced his departure from Liverpool after nine years as the Reds' most prolific goalscorer ever; it is now clear that the 32-year-old will continue his career in Turkey. Just not at Besiktas, as had been heavily rumored.
According to Turkish media reports, Salah and Trabzonspor have now agreed on a two-year contract and an annual salary of around €17 (!) million.
The Turkish club confirmed the negotiations with the player.
#turkish #year #fabrizio #sabuncuo
After leaving Anfield on a free transfer, he is joining Turkish Cup winners Trabzonspor. This is reported by transfer insider 'Fabrizio Romano' and Turkish transfer insider 'Yağız Sabuncuoğlu'.
Back in March, the Egyptian announced his departure from Liverpool after nine years as the Reds' most prolific goalscorer ever; it is now clear that the 32-year-old will continue his career in Turkey. Just not at Besiktas, as had been heavily rumored.
According to Turkish media reports, Salah and Trabzonspor have now agreed on a two-year contract and an annual salary of around €17 (!) million.
The Turkish club confirmed the negotiations with the player.
#turkish #year #fabrizio #sabuncuo
3 months ago
Nedim Bajrami is expected to leave Rangers in the coming days, with a return to Italian football emerging as the most likely destination for the 27-year-old Albania winger. (Inside Ibrox)
Leicester City and Swansea City are leading the race to sign John Souttar, with the 29-year-old Scotland centre-half certain to end his four years with Rangers. (Rangers Review)
Rangers and Cardiff City face serious competition for Tromso midfielder Jens Hjerto-Dahl, with Hull City now very interested in the 20-year-old. (Rune Robertsen on X)
Trabzonspor are to make a transfer bid of a one-season loan with an £8.6m purchase option for Besiktas winger Vaclav Cerny, the 28-year-old who spent a year on loan with Rangers. (MyNet)
League One club Luton Town have held talks with Rangers over a move for 23-year-old winger Ross McCausland. (Rangers Review)
#year #italian
Leicester City and Swansea City are leading the race to sign John Souttar, with the 29-year-old Scotland centre-half certain to end his four years with Rangers. (Rangers Review)
Rangers and Cardiff City face serious competition for Tromso midfielder Jens Hjerto-Dahl, with Hull City now very interested in the 20-year-old. (Rune Robertsen on X)
Trabzonspor are to make a transfer bid of a one-season loan with an £8.6m purchase option for Besiktas winger Vaclav Cerny, the 28-year-old who spent a year on loan with Rangers. (MyNet)
League One club Luton Town have held talks with Rangers over a move for 23-year-old winger Ross McCausland. (Rangers Review)
#year #italian
3 months ago
Arsenal have finalised the £34m acquisition of Greece international Christos Tzolis from Club Brugge.
The 24-year-old has signed a five-year contract with the Premier League champions, replacing Leandro Trossard following his Besiktas switch.
Tzolis’ move to the Emirates Stadium – ****** nal’s third permanent summer transfer – comes 48 hours after the north Londoners missed Morgan Rogers, who signed a £117m British-record fee with Chelsea, describing his new employers as the "biggest club in London".
Tzolis scored 43 times in 108 appearances for Club Brugge, and notably featured in the Belgians’ 3-0 Champions League defeat to Mikel Arteta’s side last season.
Arsenal’s sporting director Andrea Berta said: “We’re delighted to have completed the signing of Christos Tzolis.
#tzolis #arsenal #league
The 24-year-old has signed a five-year contract with the Premier League champions, replacing Leandro Trossard following his Besiktas switch.
Tzolis’ move to the Emirates Stadium – ****** nal’s third permanent summer transfer – comes 48 hours after the north Londoners missed Morgan Rogers, who signed a £117m British-record fee with Chelsea, describing his new employers as the "biggest club in London".
Tzolis scored 43 times in 108 appearances for Club Brugge, and notably featured in the Belgians’ 3-0 Champions League defeat to Mikel Arteta’s side last season.
Arsenal’s sporting director Andrea Berta said: “We’re delighted to have completed the signing of Christos Tzolis.
#tzolis #arsenal #league
